INTRODUCTION
Bile-salt-stimulated lipase (BSSL; EC 3.1.1.3) is an important digestive enzyme originally found in the milk of humans and certain other primates [1, 2] . In 1986 this lipase was also discovered in dog and cat milk [3] . The milk from many other animals, including the rat, guinea pig, rabbit, goat, cow, pig, horse and Rhesus monkey, have all tested negative for the presence of BSSL [2, 4] . It was postulated by Freed et al. [3] that the exclusive occurrence of BSSL in milk from higher primates and carnivores might be related to the composition of milk fat in the various species.
Several groups have reported BSSL to be a glycoprotein with a single polypeptide chain. The molecular mass of the enzyme has been determined by SDS/PAGE to be 125 kDa [5, 6] , 112 kDa [7] , 100 kDa [8] and 90 kDa [9] . In addition, the molecular mass of BSSL was determined to be 107 kDa by sedimentationequilibrium centrifugation [10] . It has been suggested that differences in the reported molecular mass of BSSL are due to variations in the mobility of this glycoprotein in different electrophoresis systems [I1] .
Baba et al. [12] have very recently reported possible evidence for the existence of two variants of the cDNA for human BSSL, although they did not find any evidence for the expression of the second cDNA. The two variants were reported to be identical except for the deletion of 198 bases in the smaller form. Because the nucleotide sequences of the long and short cDNAs were otherwise identical, it was suggested that they may be products of the same gene, and could have been produced by alternative splicing of the BSSL mRNA precursor. No protein corresponding to the smaller cDNA was found.
We report here the separation of two active forms of human milk BSSL, demonstrating that some individuals produce two forms of this enzyme in approximately equal amounts.
MATERIALS AND METHODS

Materials
Unless otherwise stated, all chemicals were purchased from Sigma Chemical Co. or Fisher Scientific. The TSK-GEL HeparinToyopearl 650M affinity packing was from Supelco (Bellefonte, PA, U.S.A. The buffer used for the assays and the stock solution of bile salt activator (100 mM-sodium taurocholate) was 50 mM-Tris/ HC1/0.40 M-NaCl (pH 7.5). Buffer was equilibrated at 25°C and then mixed with taurocholate (when used) and 20-100 4u1 of enzyme solution. After incubation of this mixture for 2 min at 25°C, the reaction was initiated by addition of 10 ,ul of substrate. The final assay volume was I ml and contained 1 % (v/v) acetonitrile, 2 mM-taurocholate and I mm substrate. The initial rate of 4-nitrophenol production was determined by monitoring the increase in A418 with a spectrophotometer interfaced to a Hewlett-Packard Vectra computer. Thq molar absorption coefficient of 4-nitrophenol is 11 500 M1* cmv' at 418 nm and pH 7.5 [14] . One unit of enzyme is defined as! the activity producing 1 ,tmol of product/min. The purified enzyme had a specific activity of 100-150 units/mg of protein.
PAGE SDS/PAGE was carried out in 7%-acrylamide gels as described by Laemmli [15] . The molecular-mass markers were carbonic anhydrase (29 kDa), egg albumin (45 kDa), BSA (66 kDa), rabbit muscle phosphorylase b (97.4 kDa) and Escherichia coli fl-galactosidase (116 kDa). The gel was stained with Coomassie Blue.
Enzyme purification
A 35 ml sample of human milk was centrifuged at 29000 g for 45 min in a Sorvall RC-2B refrigerated centrifuge and a model SS-34 rotor. After removal of the cream, the pH of the skim milk was adjusted to 4.6 with HCI. The milk was then heated at 40°C for 30 min to precipitate the caseins. The milk whey was obtained by centrifuging as above to remove the precipitate and then decanting the whey. Milk whey contained approx. 15 mg of protein/ml. A 15 ml sample loop constructed of Teflon tubing (1.5 mm internal diam.) was filled with milk whey, and the whey was injected on to the heparin-Toyopearl affinity column as described by Gisch et al. [16] . The affinity column was a 30 cm x 2.5 cm Abbreviations used: BSSL, bile-salt-stimulated lipase; CEH, carboxylic-ester hydrolase. * To whom all correspondence should be addressed.
glass column containing 100 ml of the heparin-Toyopearl resin. A linear gradient was run at 2.0 ml/min with 20 mM-Tris/HCl (pH 7.5) as buffer A and 20 mM-Tris/HCl/ 1.0 M-NaCl (pH 7.5) as buffer B. The gradient program was as follows: 0 % B for the first 20 min, then to 100% B in 65 min, hold at 100% B for 85 min, and then return to 0 % B in 1 min. Peaks were assayed for protein and BSSL activity as described above. The peak with BSSL activity contained 15-20 ml at approx. 0.3 mg of protein/ml, and was termed crude BSSL.
After a 5-fold concentration of the crude BSSL, 100 ,1 portions of it were injected on to a Pharmacia Superose 12 size-exclusion column (10 mm x 300 mm). Proteins were eluted from the column with 50 mM-Tris/HCI/0.40 M-NaCl (pH 7.5) at a flow rate of 0.15 ml/min. After 85 min the flow was increased to 0.40 ml/min to elute the last peak more quickly. Peaks with BSSL activity were subjected to SDS/PAGE as described above.
In one case the above purification scheme was carried out in the presence of proteinase inhibitors. The following inhibitors were added to a 40 ml milk sample from donor A: pepstatin (1 mg), phenylmethanesulphonyl fluoride (7 mg) and hydrocinnamic acid (12 mg). After the first centrifugation and removal of cream, the same amounts of inhibitors were again added to the milk sample. The buffers used for the heparin-Toyopearl affinity chromatography contained 7 4uM-pepstatin, 1 mmphenylmethanesulphonyl fluoride and 2 mM-hydrocinnamic acid.
The treatment of this milk sample was otherwise identical with that described above.
RESULTS
Human milk samples from five different donors gave very similar separations on the heparin affinity column. Fig. 1 shows two of these separations. BSSL is contained in a peak (marked with an arrow) at approx. 104 min.
Further processing of the crude BSSL by size-exclusion chromatography gave three major peaks in samples from donor A (Fig. 2a) . Two of these peaks (marked with arrows) showed high BSSL activity, with the first peak (at approx. 65 min) giving specific activities of 15 units/mg in the absence of bile-salt stimulation and 110 units/mg with 2 mM-taurocholate present, whereas the second peak (at approx. 72 min) gave 14 units/mg and 120 units/mg respectively. Preliminary studies indicate that the two forms are in approximately equal amounts in milk from donor A. The molecular masses of these two active forms of BSSL were determined to be 97 and 120 kDa by SDS/PAGE (Fig. 3) . The electrophoretic bands were rather broad, and in that respect were similar to the one band reported by Abouakil et al. [7] for immunoaffinity-purified BSSL. (Fig. la) . Lanes 3 and 4 are the first BSSL peak (65 min) from the size-exclusion column (Fig. 2a) . Lanes 5 and 6 are the second BSSL peak (72 min) from the size-exclusion column (Fig. 2a) . Conditions as stated in the text.
When a milk sample from donor A was treated with proteinase inhibitors during the BSSL purification, the same BSSL peaks were found in both the affinity chromatography and the sizeexclusion chromatography. Neither of the two peaks (65 min and 72 min) from the size-exclusion column had enzyme activity when assayed in the absence of bile-salt stimulation, and each showed less than 250% of normal activity in the presence of 2 mM-taurocholate. This decreased activity was not unexpected, since BSSL is known to be inhibited by phenylmethanesulphonyl fluoride [7] .
The samples from the other four donors, as represented by donor B, each yielded two peaks by size-exclusion chromatography (Fig. 2b) , and only one peak (at approx. 66min) had BSSL activity. This peak had specific activities of 9.3 units/mg without bile-salt stimulation and 150 units/mg in the presence of 2 mM-taurocholate. enzyme form to produce a smaller (but still active) form. This is unlikely to be the case, since the presence of proteinase inhibitors during the purification did not affect the results.
The possibility of differences in the extent or type of posttranslational glycosylation as an explanation for the two forms of BSSL cannot be ruled out at present, but this would require different reactions in donor A as compared with the other donors.
Alternative splicing of the BSSL mRNA precursor could also explain the existence of two forms of BSSL. Baba et al. [12] reported finding two versions of BSSL cDNA, although they only detected the expression of one BSSL protein. We, however, have found approximately equal amounts of two enzyme forms in one subject, and only one detectable form in the other four subjects. It is unclear whether the two forms of BSSL that we have separated are related to the cDNAs reported by Baba et al. [12] , even though it is conceivable that individual differences in the regulation of the alternative splicing could account for different yields of the two enzyme forms [17] . The molecular mass difference of our two enzyme forms is approx. 23 kDa, which is more than the difference of 198 bases (66 amino acids) reported for the cDNAs by Baba et al. [12] would account for. It is possible that glycosylation could amplify the apparent molecularmass loss, although no glycosylation sites were specifically identified among the deleted 198 bases [12] .
Another plausible explanation for the two forms of BSSL would be co-dominant alleles, such as occurs in the amylase system of Drosophila [18] . If donor A was heterozygous and donor B was homozygous, co-dominant alleles would explain the observed results.
An alternative explanation for our findings would be posttranscriptional editing of the mRNA for BSSL, as in the case of apolipoprotein B [19] .
BSSL has many properties in common with pancreatic carboxylic-ester hydrolase (CEH; EC 3.1.1.1), and because of their great similarity it has been suggested that BSSL and CEH may be identical, and that BSSL may represent a pancreatic protein which is also secreted by lactating mammary glands [7, 11] . The main reported difference between the two enzymes is in molecular mass, with that of BSSL being about 100% higher than that of CEH, although the wide variability in the reported molecular mass of BSSL overlaps the range for CEH, allowing the possibility of the two enzymes being identical. The question of whether BSSL and CEH are identical is now complicated by the fact that BSSL can exist in two different forms.
Note added in proof (received 3 February 1992) Milk from a sixth donor has yielded two forms of BSSL. From a total of six subjects, two donors have had the two forms of BSSL and the other four have each had only the larger form of the enzyme.
DISCUSSION
Two active forms of human BSSL were found in the milk from 
